Pharma & Healthcare
Global Oligonucleotide Therapeutics Market Research Report 2024
- Oct 12, 24
- ID: 30149
- Pages: 96
- Figures: 99
- Views: 47
Oligonucleotide therapeutics are a class of precision medicines composed of short DNA or RNA sequences designed to specifically target and modulate the expression of genes involved in disease processes. These therapies can act by silencing, inhibiting, or correcting genetic abnormalities at the molecular level, offering a highly targeted approach to treat various conditions such as genetic disorders, cancers, and viral infections. Oligonucleotide therapeutics include antisense oligonucleotides, small interfering RNA (siRNA), and aptamers, and they represent a promising area of drug development due to their ability to address previously untreatable diseases.
The global Oligonucleotide Therapeutics market was valued at US$ 12490 million in 2023 and is anticipated to reach US$ 9377 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
Key driver of the oligonucleotide therapeutics market is the growing prevalence of genetic and rare diseases that require precise and targeted treatment options. Advances in genomics and personalized medicine have fueled interest in oligonucleotide therapies, which can directly modulate gene expression and offer solutions for conditions that were previously difficult to treat. The success of approved oligonucleotide drugs, such as antisense oligonucleotides and siRNA therapies, has increased confidence in this field, leading to more investments and research in developing novel treatments for a wide range of diseases, including cancers and neurological disorders.
One significant challenge in the oligonucleotide therapeutics market is the complexity of delivering these molecules effectively to target cells or tissues. Oligonucleotides are large, negatively charged molecules that face hurdles in stability, bioavailability, and efficient cellular uptake. Developing delivery systems that can ensure targeted and sustained delivery while minimizing immune responses or off-target effects remains a critical challenge. Additionally, the high costs associated with research, development, and manufacturing of oligonucleotide-based drugs pose financial challenges, limiting accessibility and widespread adoption, especially in resource-constrained healthcare settings.
Europe is the largest consumption place, with a consumption market share nearly 44.61% in 2023. Following Europe, North Americas is the second largest consumption place with the consumption market share of 34.9%. The global key companies of oligonucleotide therapeutics include Pfizer, Moderna Therapeutics, BioNTech, Biogen, Alnylam, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, Novartis, Sobi, Ionis Pharmaceuticals, etc. In 2023, the global top five players had a share approximately 97.87% in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Therapeutics.
The Oligonucleotide Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oligonucleotide Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Segment by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Oligonucleotide Therapeutics market was valued at US$ 12490 million in 2023 and is anticipated to reach US$ 9377 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
Key driver of the oligonucleotide therapeutics market is the growing prevalence of genetic and rare diseases that require precise and targeted treatment options. Advances in genomics and personalized medicine have fueled interest in oligonucleotide therapies, which can directly modulate gene expression and offer solutions for conditions that were previously difficult to treat. The success of approved oligonucleotide drugs, such as antisense oligonucleotides and siRNA therapies, has increased confidence in this field, leading to more investments and research in developing novel treatments for a wide range of diseases, including cancers and neurological disorders.
One significant challenge in the oligonucleotide therapeutics market is the complexity of delivering these molecules effectively to target cells or tissues. Oligonucleotides are large, negatively charged molecules that face hurdles in stability, bioavailability, and efficient cellular uptake. Developing delivery systems that can ensure targeted and sustained delivery while minimizing immune responses or off-target effects remains a critical challenge. Additionally, the high costs associated with research, development, and manufacturing of oligonucleotide-based drugs pose financial challenges, limiting accessibility and widespread adoption, especially in resource-constrained healthcare settings.
Europe is the largest consumption place, with a consumption market share nearly 44.61% in 2023. Following Europe, North Americas is the second largest consumption place with the consumption market share of 34.9%. The global key companies of oligonucleotide therapeutics include Pfizer, Moderna Therapeutics, BioNTech, Biogen, Alnylam, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, Novartis, Sobi, Ionis Pharmaceuticals, etc. In 2023, the global top five players had a share approximately 97.87% in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Therapeutics.
The Oligonucleotide Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oligonucleotide Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Segment by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antisense Oligonucleotides (ASO)
1.2.3 siRNA
1.2.4 mRNA
1.3 Market by Application
1.3.1 Global Oligonucleotide Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 COVID-19
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide Therapeutics Market Perspective (2019-2030)
2.2 Global Oligonucleotide Therapeutics Growth Trends by Region
2.2.1 Global Oligonucleotide Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oligonucleotide Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Oligonucleotide Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Oligonucleotide Therapeutics Market Dynamics
2.3.1 Oligonucleotide Therapeutics Industry Trends
2.3.2 Oligonucleotide Therapeutics Market Drivers
2.3.3 Oligonucleotide Therapeutics Market Challenges
2.3.4 Oligonucleotide Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide Therapeutics Players by Revenue
3.1.1 Global Top Oligonucleotide Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Oligonucleotide Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oligonucleotide Therapeutics Revenue
3.4 Global Oligonucleotide Therapeutics Market Concentration Ratio
3.4.1 Global Oligonucleotide Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Therapeutics Revenue in 2023
3.5 Global Key Players of Oligonucleotide Therapeutics Head office and Area Served
3.6 Global Key Players of Oligonucleotide Therapeutics, Product and Application
3.7 Global Key Players of Oligonucleotide Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide Therapeutics Breakdown Data by Type
4.1 Global Oligonucleotide Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2025-2030)
5 Oligonucleotide Therapeutics Breakdown Data by Application
5.1 Global Oligonucleotide Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oligonucleotide Therapeutics Market Size (2019-2030)
6.2 North America Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oligonucleotide Therapeutics Market Size by Country (2019-2024)
6.4 North America Oligonucleotide Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide Therapeutics Market Size (2019-2030)
7.2 Europe Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oligonucleotide Therapeutics Market Size by Country (2019-2024)
7.4 Europe Oligonucleotide Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oligonucleotide Therapeutics Market Size (2019-2030)
9.2 Latin America Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oligonucleotide Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Oligonucleotide Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Oligonucleotide Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.1.5 Sarepta Therapeutics Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Details
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Oligonucleotide Therapeutics Introduction
11.2.4 Ionis Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Alnylam
11.3.1 Alnylam Company Details
11.3.2 Alnylam Business Overview
11.3.3 Alnylam Oligonucleotide Therapeutics Introduction
11.3.4 Alnylam Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.3.5 Alnylam Recent Development
11.4 Biogen
11.4.1 Biogen Company Details
11.4.2 Biogen Business Overview
11.4.3 Biogen Oligonucleotide Therapeutics Introduction
11.4.4 Biogen Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.4.5 Biogen Recent Development
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Details
11.5.2 Nippon Shinyaku Business Overview
11.5.3 Nippon Shinyaku Oligonucleotide Therapeutics Introduction
11.5.4 Nippon Shinyaku Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.5.5 Nippon Shinyaku Recent Development
11.6 Sobi
11.6.1 Sobi Company Details
11.6.2 Sobi Business Overview
11.6.3 Sobi Oligonucleotide Therapeutics Introduction
11.6.4 Sobi Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.6.5 Sobi Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Oligonucleotide Therapeutics Introduction
11.7.4 Novartis Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 BioNTech
11.8.1 BioNTech Company Details
11.8.2 BioNTech Business Overview
11.8.3 BioNTech Oligonucleotide Therapeutics Introduction
11.8.4 BioNTech Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.8.5 BioNTech Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Oligonucleotide Therapeutics Introduction
11.9.4 Pfizer Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Details
11.10.2 Moderna Therapeutics Business Overview
11.10.3 Moderna Therapeutics Oligonucleotide Therapeutics Introduction
11.10.4 Moderna Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.10.5 Moderna Therapeutics Recent Development
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Details
11.11.2 Jazz Pharmaceuticals Business Overview
11.11.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Introduction
11.11.4 Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.11.5 Jazz Pharmaceuticals Recent Development
11.12 CureVac
11.12.1 CureVac Company Details
11.12.2 CureVac Business Overview
11.12.3 CureVac Oligonucleotide Therapeutics Introduction
11.12.4 CureVac Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.12.5 CureVac Recent Development
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Details
11.13.2 Regulus Therapeutics Business Overview
11.13.3 Regulus Therapeutics Oligonucleotide Therapeutics Introduction
11.13.4 Regulus Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.13.5 Regulus Therapeutics Recent Development
11.14 ProQR
11.14.1 ProQR Company Details
11.14.2 ProQR Business Overview
11.14.3 ProQR Oligonucleotide Therapeutics Introduction
11.14.4 ProQR Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.14.5 ProQR Recent Development
11.15 Secarna
11.15.1 Secarna Company Details
11.15.2 Secarna Business Overview
11.15.3 Secarna Oligonucleotide Therapeutics Introduction
11.15.4 Secarna Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.15.5 Secarna Recent Development
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Details
11.16.2 MiNA Therapeutics Business Overview
11.16.3 MiNA Therapeutics Oligonucleotide Therapeutics Introduction
11.16.4 MiNA Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.16.5 MiNA Therapeutics Recent Development
11.17 Sylentis
11.17.1 Sylentis Company Details
11.17.2 Sylentis Business Overview
11.17.3 Sylentis Oligonucleotide Therapeutics Introduction
11.17.4 Sylentis Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.17.5 Sylentis Recent Development
11.18 Arrowhead
11.18.1 Arrowhead Company Details
11.18.2 Arrowhead Business Overview
11.18.3 Arrowhead Oligonucleotide Therapeutics Introduction
11.18.4 Arrowhead Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.18.5 Arrowhead Recent Development
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Details
11.19.2 Silence Therapeutics Business Overview
11.19.3 Silence Therapeutics Oligonucleotide Therapeutics Introduction
11.19.4 Silence Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.19.5 Silence Therapeutics Recent Development
11.20 Dicerna
11.20.1 Dicerna Company Details
11.20.2 Dicerna Business Overview
11.20.3 Dicerna Oligonucleotide Therapeutics Introduction
11.20.4 Dicerna Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.20.5 Dicerna Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antisense Oligonucleotides (ASO)
1.2.3 siRNA
1.2.4 mRNA
1.3 Market by Application
1.3.1 Global Oligonucleotide Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 COVID-19
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide Therapeutics Market Perspective (2019-2030)
2.2 Global Oligonucleotide Therapeutics Growth Trends by Region
2.2.1 Global Oligonucleotide Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oligonucleotide Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Oligonucleotide Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Oligonucleotide Therapeutics Market Dynamics
2.3.1 Oligonucleotide Therapeutics Industry Trends
2.3.2 Oligonucleotide Therapeutics Market Drivers
2.3.3 Oligonucleotide Therapeutics Market Challenges
2.3.4 Oligonucleotide Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide Therapeutics Players by Revenue
3.1.1 Global Top Oligonucleotide Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Oligonucleotide Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oligonucleotide Therapeutics Revenue
3.4 Global Oligonucleotide Therapeutics Market Concentration Ratio
3.4.1 Global Oligonucleotide Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Therapeutics Revenue in 2023
3.5 Global Key Players of Oligonucleotide Therapeutics Head office and Area Served
3.6 Global Key Players of Oligonucleotide Therapeutics, Product and Application
3.7 Global Key Players of Oligonucleotide Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide Therapeutics Breakdown Data by Type
4.1 Global Oligonucleotide Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2025-2030)
5 Oligonucleotide Therapeutics Breakdown Data by Application
5.1 Global Oligonucleotide Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oligonucleotide Therapeutics Market Size (2019-2030)
6.2 North America Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oligonucleotide Therapeutics Market Size by Country (2019-2024)
6.4 North America Oligonucleotide Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide Therapeutics Market Size (2019-2030)
7.2 Europe Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oligonucleotide Therapeutics Market Size by Country (2019-2024)
7.4 Europe Oligonucleotide Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oligonucleotide Therapeutics Market Size (2019-2030)
9.2 Latin America Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oligonucleotide Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Oligonucleotide Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Oligonucleotide Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Oligonucleotide Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.1.5 Sarepta Therapeutics Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Details
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Oligonucleotide Therapeutics Introduction
11.2.4 Ionis Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Alnylam
11.3.1 Alnylam Company Details
11.3.2 Alnylam Business Overview
11.3.3 Alnylam Oligonucleotide Therapeutics Introduction
11.3.4 Alnylam Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.3.5 Alnylam Recent Development
11.4 Biogen
11.4.1 Biogen Company Details
11.4.2 Biogen Business Overview
11.4.3 Biogen Oligonucleotide Therapeutics Introduction
11.4.4 Biogen Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.4.5 Biogen Recent Development
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Details
11.5.2 Nippon Shinyaku Business Overview
11.5.3 Nippon Shinyaku Oligonucleotide Therapeutics Introduction
11.5.4 Nippon Shinyaku Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.5.5 Nippon Shinyaku Recent Development
11.6 Sobi
11.6.1 Sobi Company Details
11.6.2 Sobi Business Overview
11.6.3 Sobi Oligonucleotide Therapeutics Introduction
11.6.4 Sobi Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.6.5 Sobi Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Oligonucleotide Therapeutics Introduction
11.7.4 Novartis Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 BioNTech
11.8.1 BioNTech Company Details
11.8.2 BioNTech Business Overview
11.8.3 BioNTech Oligonucleotide Therapeutics Introduction
11.8.4 BioNTech Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.8.5 BioNTech Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Oligonucleotide Therapeutics Introduction
11.9.4 Pfizer Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Details
11.10.2 Moderna Therapeutics Business Overview
11.10.3 Moderna Therapeutics Oligonucleotide Therapeutics Introduction
11.10.4 Moderna Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.10.5 Moderna Therapeutics Recent Development
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Details
11.11.2 Jazz Pharmaceuticals Business Overview
11.11.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Introduction
11.11.4 Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.11.5 Jazz Pharmaceuticals Recent Development
11.12 CureVac
11.12.1 CureVac Company Details
11.12.2 CureVac Business Overview
11.12.3 CureVac Oligonucleotide Therapeutics Introduction
11.12.4 CureVac Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.12.5 CureVac Recent Development
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Details
11.13.2 Regulus Therapeutics Business Overview
11.13.3 Regulus Therapeutics Oligonucleotide Therapeutics Introduction
11.13.4 Regulus Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.13.5 Regulus Therapeutics Recent Development
11.14 ProQR
11.14.1 ProQR Company Details
11.14.2 ProQR Business Overview
11.14.3 ProQR Oligonucleotide Therapeutics Introduction
11.14.4 ProQR Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.14.5 ProQR Recent Development
11.15 Secarna
11.15.1 Secarna Company Details
11.15.2 Secarna Business Overview
11.15.3 Secarna Oligonucleotide Therapeutics Introduction
11.15.4 Secarna Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.15.5 Secarna Recent Development
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Details
11.16.2 MiNA Therapeutics Business Overview
11.16.3 MiNA Therapeutics Oligonucleotide Therapeutics Introduction
11.16.4 MiNA Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.16.5 MiNA Therapeutics Recent Development
11.17 Sylentis
11.17.1 Sylentis Company Details
11.17.2 Sylentis Business Overview
11.17.3 Sylentis Oligonucleotide Therapeutics Introduction
11.17.4 Sylentis Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.17.5 Sylentis Recent Development
11.18 Arrowhead
11.18.1 Arrowhead Company Details
11.18.2 Arrowhead Business Overview
11.18.3 Arrowhead Oligonucleotide Therapeutics Introduction
11.18.4 Arrowhead Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.18.5 Arrowhead Recent Development
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Details
11.19.2 Silence Therapeutics Business Overview
11.19.3 Silence Therapeutics Oligonucleotide Therapeutics Introduction
11.19.4 Silence Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.19.5 Silence Therapeutics Recent Development
11.20 Dicerna
11.20.1 Dicerna Company Details
11.20.2 Dicerna Business Overview
11.20.3 Dicerna Oligonucleotide Therapeutics Introduction
11.20.4 Dicerna Revenue in Oligonucleotide Therapeutics Business (2019-2024)
11.20.5 Dicerna Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Antisense Oligonucleotides (ASO)
Table 3. Key Players of siRNA
Table 4. Key Players of mRNA
Table 5. Global Oligonucleotide Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Oligonucleotide Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Oligonucleotide Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Oligonucleotide Therapeutics Market Share by Region (2019-2024)
Table 9. Global Oligonucleotide Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Oligonucleotide Therapeutics Market Share by Region (2025-2030)
Table 11. Oligonucleotide Therapeutics Market Trends
Table 12. Oligonucleotide Therapeutics Market Drivers
Table 13. Oligonucleotide Therapeutics Market Challenges
Table 14. Oligonucleotide Therapeutics Market Restraints
Table 15. Global Oligonucleotide Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Oligonucleotide Therapeutics Market Share by Players (2019-2024)
Table 17. Global Top Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapeutics as of 2023)
Table 18. Ranking of Global Top Oligonucleotide Therapeutics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Oligonucleotide Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Global Key Players of Oligonucleotide Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Oligonucleotide Therapeutics, Product and Application
Table 22. Global Key Players of Oligonucleotide Therapeutics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oligonucleotide Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2019-2024)
Table 26. Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2025-2030)
Table 28. Global Oligonucleotide Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2019-2024)
Table 30. Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2025-2030)
Table 32. North America Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Sarepta Therapeutics Company Details
Table 48. Sarepta Therapeutics Business Overview
Table 49. Sarepta Therapeutics Oligonucleotide Therapeutics Product
Table 50. Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 51. Sarepta Therapeutics Recent Development
Table 52. Ionis Pharmaceuticals Company Details
Table 53. Ionis Pharmaceuticals Business Overview
Table 54. Ionis Pharmaceuticals Oligonucleotide Therapeutics Product
Table 55. Ionis Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 56. Ionis Pharmaceuticals Recent Development
Table 57. Alnylam Company Details
Table 58. Alnylam Business Overview
Table 59. Alnylam Oligonucleotide Therapeutics Product
Table 60. Alnylam Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 61. Alnylam Recent Development
Table 62. Biogen Company Details
Table 63. Biogen Business Overview
Table 64. Biogen Oligonucleotide Therapeutics Product
Table 65. Biogen Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 66. Biogen Recent Development
Table 67. Nippon Shinyaku Company Details
Table 68. Nippon Shinyaku Business Overview
Table 69. Nippon Shinyaku Oligonucleotide Therapeutics Product
Table 70. Nippon Shinyaku Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 71. Nippon Shinyaku Recent Development
Table 72. Sobi Company Details
Table 73. Sobi Business Overview
Table 74. Sobi Oligonucleotide Therapeutics Product
Table 75. Sobi Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 76. Sobi Recent Development
Table 77. Novartis Company Details
Table 78. Novartis Business Overview
Table 79. Novartis Oligonucleotide Therapeutics Product
Table 80. Novartis Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 81. Novartis Recent Development
Table 82. BioNTech Company Details
Table 83. BioNTech Business Overview
Table 84. BioNTech Oligonucleotide Therapeutics Product
Table 85. BioNTech Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 86. BioNTech Recent Development
Table 87. Pfizer Company Details
Table 88. Pfizer Business Overview
Table 89. Pfizer Oligonucleotide Therapeutics Product
Table 90. Pfizer Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 91. Pfizer Recent Development
Table 92. Moderna Therapeutics Company Details
Table 93. Moderna Therapeutics Business Overview
Table 94. Moderna Therapeutics Oligonucleotide Therapeutics Product
Table 95. Moderna Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 96. Moderna Therapeutics Recent Development
Table 97. Jazz Pharmaceuticals Company Details
Table 98. Jazz Pharmaceuticals Business Overview
Table 99. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product
Table 100. Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 101. Jazz Pharmaceuticals Recent Development
Table 102. CureVac Company Details
Table 103. CureVac Business Overview
Table 104. CureVac Oligonucleotide Therapeutics Product
Table 105. CureVac Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 106. CureVac Recent Development
Table 107. Regulus Therapeutics Company Details
Table 108. Regulus Therapeutics Business Overview
Table 109. Regulus Therapeutics Oligonucleotide Therapeutics Product
Table 110. Regulus Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 111. Regulus Therapeutics Recent Development
Table 112. ProQR Company Details
Table 113. ProQR Business Overview
Table 114. ProQR Oligonucleotide Therapeutics Product
Table 115. ProQR Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 116. ProQR Recent Development
Table 117. Secarna Company Details
Table 118. Secarna Business Overview
Table 119. Secarna Oligonucleotide Therapeutics Product
Table 120. Secarna Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 121. Secarna Recent Development
Table 122. MiNA Therapeutics Company Details
Table 123. MiNA Therapeutics Business Overview
Table 124. MiNA Therapeutics Oligonucleotide Therapeutics Product
Table 125. MiNA Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 126. MiNA Therapeutics Recent Development
Table 127. Sylentis Company Details
Table 128. Sylentis Business Overview
Table 129. Sylentis Oligonucleotide Therapeutics Product
Table 130. Sylentis Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 131. Sylentis Recent Development
Table 132. Arrowhead Company Details
Table 133. Arrowhead Business Overview
Table 134. Arrowhead Oligonucleotide Therapeutics Product
Table 135. Arrowhead Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 136. Arrowhead Recent Development
Table 137. Silence Therapeutics Company Details
Table 138. Silence Therapeutics Business Overview
Table 139. Silence Therapeutics Oligonucleotide Therapeutics Product
Table 140. Silence Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 141. Silence Therapeutics Recent Development
Table 142. Dicerna Company Details
Table 143. Dicerna Business Overview
Table 144. Dicerna Oligonucleotide Therapeutics Product
Table 145. Dicerna Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 146. Dicerna Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
Table 150. Authors List of This Report
List of Figures
Figure 1. Oligonucleotide Therapeutics Picture
Figure 2. Global Oligonucleotide Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Oligonucleotide Therapeutics Market Share by Type: 2023 VS 2030
Figure 4. Antisense Oligonucleotides (ASO) Features
Figure 5. siRNA Features
Figure 6. mRNA Features
Figure 7. Global Oligonucleotide Therapeutics Market Size by Application (2024-2030) & (US$ Million)
Figure 8. Global Oligonucleotide Therapeutics Market Share by Application: 2023 VS 2030
Figure 9. Neuromuscular Diseases Case Studies
Figure 10. hATTR Case Studies
Figure 11. COVID-19 Case Studies
Figure 12. Other Case Studies
Figure 13. Oligonucleotide Therapeutics Report Years Considered
Figure 14. Global Oligonucleotide Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Oligonucleotide Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Oligonucleotide Therapeutics Market Share by Region: 2023 VS 2030
Figure 17. Global Oligonucleotide Therapeutics Market Share by Players in 2023
Figure 18. Global Top Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapeutics as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Oligonucleotide Therapeutics Revenue in 2023
Figure 20. North America Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 22. United States Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 26. Germany Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Oligonucleotide Therapeutics Market Share by Region (2019-2030)
Figure 34. China Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 42. Mexico Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 46. Turkey Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. UAE Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Sarepta Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 50. Ionis Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 51. Alnylam Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 52. Biogen Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 53. Nippon Shinyaku Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 54. Sobi Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 55. Novartis Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 56. BioNTech Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 57. Pfizer Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 58. Moderna Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 59. Jazz Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 60. CureVac Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 61. Regulus Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 62. ProQR Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 63. Secarna Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 64. MiNA Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 65. Sylentis Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 66. Arrowhead Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 67. Silence Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 68. Dicerna Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Table 1. Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Antisense Oligonucleotides (ASO)
Table 3. Key Players of siRNA
Table 4. Key Players of mRNA
Table 5. Global Oligonucleotide Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Oligonucleotide Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Oligonucleotide Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Oligonucleotide Therapeutics Market Share by Region (2019-2024)
Table 9. Global Oligonucleotide Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Oligonucleotide Therapeutics Market Share by Region (2025-2030)
Table 11. Oligonucleotide Therapeutics Market Trends
Table 12. Oligonucleotide Therapeutics Market Drivers
Table 13. Oligonucleotide Therapeutics Market Challenges
Table 14. Oligonucleotide Therapeutics Market Restraints
Table 15. Global Oligonucleotide Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Oligonucleotide Therapeutics Market Share by Players (2019-2024)
Table 17. Global Top Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapeutics as of 2023)
Table 18. Ranking of Global Top Oligonucleotide Therapeutics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Oligonucleotide Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Global Key Players of Oligonucleotide Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Oligonucleotide Therapeutics, Product and Application
Table 22. Global Key Players of Oligonucleotide Therapeutics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oligonucleotide Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2019-2024)
Table 26. Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2025-2030)
Table 28. Global Oligonucleotide Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2019-2024)
Table 30. Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2025-2030)
Table 32. North America Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Sarepta Therapeutics Company Details
Table 48. Sarepta Therapeutics Business Overview
Table 49. Sarepta Therapeutics Oligonucleotide Therapeutics Product
Table 50. Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 51. Sarepta Therapeutics Recent Development
Table 52. Ionis Pharmaceuticals Company Details
Table 53. Ionis Pharmaceuticals Business Overview
Table 54. Ionis Pharmaceuticals Oligonucleotide Therapeutics Product
Table 55. Ionis Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 56. Ionis Pharmaceuticals Recent Development
Table 57. Alnylam Company Details
Table 58. Alnylam Business Overview
Table 59. Alnylam Oligonucleotide Therapeutics Product
Table 60. Alnylam Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 61. Alnylam Recent Development
Table 62. Biogen Company Details
Table 63. Biogen Business Overview
Table 64. Biogen Oligonucleotide Therapeutics Product
Table 65. Biogen Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 66. Biogen Recent Development
Table 67. Nippon Shinyaku Company Details
Table 68. Nippon Shinyaku Business Overview
Table 69. Nippon Shinyaku Oligonucleotide Therapeutics Product
Table 70. Nippon Shinyaku Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 71. Nippon Shinyaku Recent Development
Table 72. Sobi Company Details
Table 73. Sobi Business Overview
Table 74. Sobi Oligonucleotide Therapeutics Product
Table 75. Sobi Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 76. Sobi Recent Development
Table 77. Novartis Company Details
Table 78. Novartis Business Overview
Table 79. Novartis Oligonucleotide Therapeutics Product
Table 80. Novartis Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 81. Novartis Recent Development
Table 82. BioNTech Company Details
Table 83. BioNTech Business Overview
Table 84. BioNTech Oligonucleotide Therapeutics Product
Table 85. BioNTech Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 86. BioNTech Recent Development
Table 87. Pfizer Company Details
Table 88. Pfizer Business Overview
Table 89. Pfizer Oligonucleotide Therapeutics Product
Table 90. Pfizer Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 91. Pfizer Recent Development
Table 92. Moderna Therapeutics Company Details
Table 93. Moderna Therapeutics Business Overview
Table 94. Moderna Therapeutics Oligonucleotide Therapeutics Product
Table 95. Moderna Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 96. Moderna Therapeutics Recent Development
Table 97. Jazz Pharmaceuticals Company Details
Table 98. Jazz Pharmaceuticals Business Overview
Table 99. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product
Table 100. Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 101. Jazz Pharmaceuticals Recent Development
Table 102. CureVac Company Details
Table 103. CureVac Business Overview
Table 104. CureVac Oligonucleotide Therapeutics Product
Table 105. CureVac Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 106. CureVac Recent Development
Table 107. Regulus Therapeutics Company Details
Table 108. Regulus Therapeutics Business Overview
Table 109. Regulus Therapeutics Oligonucleotide Therapeutics Product
Table 110. Regulus Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 111. Regulus Therapeutics Recent Development
Table 112. ProQR Company Details
Table 113. ProQR Business Overview
Table 114. ProQR Oligonucleotide Therapeutics Product
Table 115. ProQR Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 116. ProQR Recent Development
Table 117. Secarna Company Details
Table 118. Secarna Business Overview
Table 119. Secarna Oligonucleotide Therapeutics Product
Table 120. Secarna Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 121. Secarna Recent Development
Table 122. MiNA Therapeutics Company Details
Table 123. MiNA Therapeutics Business Overview
Table 124. MiNA Therapeutics Oligonucleotide Therapeutics Product
Table 125. MiNA Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 126. MiNA Therapeutics Recent Development
Table 127. Sylentis Company Details
Table 128. Sylentis Business Overview
Table 129. Sylentis Oligonucleotide Therapeutics Product
Table 130. Sylentis Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 131. Sylentis Recent Development
Table 132. Arrowhead Company Details
Table 133. Arrowhead Business Overview
Table 134. Arrowhead Oligonucleotide Therapeutics Product
Table 135. Arrowhead Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 136. Arrowhead Recent Development
Table 137. Silence Therapeutics Company Details
Table 138. Silence Therapeutics Business Overview
Table 139. Silence Therapeutics Oligonucleotide Therapeutics Product
Table 140. Silence Therapeutics Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 141. Silence Therapeutics Recent Development
Table 142. Dicerna Company Details
Table 143. Dicerna Business Overview
Table 144. Dicerna Oligonucleotide Therapeutics Product
Table 145. Dicerna Revenue in Oligonucleotide Therapeutics Business (2019-2024) & (US$ Million)
Table 146. Dicerna Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
Table 150. Authors List of This Report
List of Figures
Figure 1. Oligonucleotide Therapeutics Picture
Figure 2. Global Oligonucleotide Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Oligonucleotide Therapeutics Market Share by Type: 2023 VS 2030
Figure 4. Antisense Oligonucleotides (ASO) Features
Figure 5. siRNA Features
Figure 6. mRNA Features
Figure 7. Global Oligonucleotide Therapeutics Market Size by Application (2024-2030) & (US$ Million)
Figure 8. Global Oligonucleotide Therapeutics Market Share by Application: 2023 VS 2030
Figure 9. Neuromuscular Diseases Case Studies
Figure 10. hATTR Case Studies
Figure 11. COVID-19 Case Studies
Figure 12. Other Case Studies
Figure 13. Oligonucleotide Therapeutics Report Years Considered
Figure 14. Global Oligonucleotide Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Oligonucleotide Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Oligonucleotide Therapeutics Market Share by Region: 2023 VS 2030
Figure 17. Global Oligonucleotide Therapeutics Market Share by Players in 2023
Figure 18. Global Top Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapeutics as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Oligonucleotide Therapeutics Revenue in 2023
Figure 20. North America Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 22. United States Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 26. Germany Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Oligonucleotide Therapeutics Market Share by Region (2019-2030)
Figure 34. China Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 42. Mexico Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Oligonucleotide Therapeutics Market Share by Country (2019-2030)
Figure 46. Turkey Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. UAE Oligonucleotide Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Sarepta Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 50. Ionis Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 51. Alnylam Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 52. Biogen Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 53. Nippon Shinyaku Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 54. Sobi Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 55. Novartis Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 56. BioNTech Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 57. Pfizer Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 58. Moderna Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 59. Jazz Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 60. CureVac Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 61. Regulus Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 62. ProQR Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 63. Secarna Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 64. MiNA Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 65. Sylentis Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 66. Arrowhead Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 67. Silence Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 68. Dicerna Revenue Growth Rate in Oligonucleotide Therapeutics Business (2019-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Smart Potentiometric Titrator - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Multifunctional Zeta Potential Analyzer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Ultrapure Water pH Sensor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232